세계의 유세포 분석 시장 규모는 2024년부터 2031년까지 예측 기간 동안 7.89%의 연평균 복합 성장률(CAGR)로 확대될 전망이며, 2023년 50억 1,000만 달러에서 2031년에는 92억 달러로 성장할 것으로 예측됩니다. 노인 인구 증가, 만성 질환 및 감염의 유병률 증가는 세계의 유세포 분석 시장의 성장을 이끌고 있습니다. 유세포 분석은 면역학, 바이러스학, 분자생물학, 암생물학, 감염증 모니터링 등 여러 분야에 응용할 수 있는 강력한 도구입니다. 또한, 최신기술 및 제품 개발을 위한 연구개발에 대한 의료비 증가는 시장을 더욱 견인할 것으로 기대됩니다.
유세포 분석의 기술 진보 및 신제품 출시는 업계에 큰 영향을 미칩니다. 주목할만 한 진전 중 하나는 다양한 기업들이 스펙트럼 유세포 분석 기술을 상업적으로 출시했다는 것입니다. 이러한 진보는 암, 면역 결핍증, 감염증 등의 질병의 유병률 증가에 대처하는데 매우 중요합니다. 맞춤형 의료, 창약, 개발에 중요한 역할을 할 것으로 기대되고 있습니다. 그러나 첨단 유세포 분석 장비의 높은 가격은 여전히 어려움이 있으며 소규모 연구시설 및 신흥 국가에서의 사용이 제한될 수 있습니다. 또한 개발도상국 및 저개발국에서 이러한 기술에 대한 접근성을 개선하기 위한 정부의 이니셔티브, 다수의 선도 기업들의 존재, 첨단 유세포 분석 장비 및 장비 설계를 위한 공개 회사와 비공개 회사 간의 지속적인 제휴는 시장 성장을 가속하고 있습니다.
세계에서 만성 질환과 감염이 증가함에 따라 유세포 분석에 대한 수요가 급증하고 있습니다. 유세포 분석은 암, HIV, 에이즈, 결핵 및 기타 많은 질병의 검출 및 분석에 중요한 역할을 합니다. 유세포 분석의 정확성과 감도에 대한 의료 전문가의 의식이 높아져 업계의 성장에 기여하고 있습니다.
WHO의 2023년 통계에 따르면 만성 질환은 세계 수준에서 매년 4,100만 명의 사망을 일으킵니다. 이것은 지역이나 국가에 관계없이 모든 연령대의 사람들에게 영향을 미칩니다. 계속 앉아있는 라이프 스타일, 건강에 해로운 식사, 과도한 담배 및 알코올 섭취는 만성 질환의 유병률 상승의 주요 위험 요소입니다. 질병과 그 원인 물질의 조기 진단, 정확한 발견, 조기 개입은 만성 질환의 만연 확대에 대항하는 유일한 해결책입니다. 따라서 건강 관리 전문가들은 유세포 분석법과 같은 고급 기술과 매우 효율적인 검사 옵션을 사용할 수 있으며, 이는 큰 성장 촉진요인이 되었습니다.
이 보고서는 세계의 유세포 분석 시장을 조사했으며, 시장 개요와 함께 제품 및 서비스별, 기술별, 용도별, 최종 사용자별, 지역별 동향 및 시장 진출기업 프로파일 등의 정보를 제공합니다.
Global flow cytometry market is projected to witness a CAGR of 7.89% during the forecast period 2024-2031, growing from USD 5.01 billion in 2023 to USD 9.2 billion in 2031. The increasing geriatric population and the rising prevalence of chronic and infectious diseases drive growth in the global flow cytometry market. Flow cytometry is a powerful tool with applications in multiple disciplines such as immunology, virology, molecular biology, cancer biology, and infectious disease monitoring. Moreover, increasing healthcare expenditure on research and development for the development of the latest technologies and products is further expected to drive the market.
Technological advancements and new product launches in flow cytometry have significantly impacted the industry. One notable development is various companies' commercial launch of spectral flow cytometry technology. These advancements are crucial in addressing the increasing prevalence of diseases, such as cancer, immunodeficiency disorders, and infectious diseases. They are expected to play a vital role in personalized medicine, drug discovery, and development. However, the high cost of advanced flow cytometry equipment remains challenging, potentially limiting accessibility for smaller research facilities or emerging countries. Moreover, government initiatives for improving access to these technologies in developing and under-developed countries, the presence of several leading players, and ongoing partnerships between public and private companies for engineering advanced flow cytometry devices and instruments are facilitating market growth.
Increasing Prevalence of Chronic and Infectious Diseases
There has been a surge in the demand for flow cytometry due to the rising number of chronic and infectious diseases worldwide. Flow cytometry plays a crucial role in detecting and analyzing diseases such as cancer, HIV, AIDS, TB, and many more. Rising awareness among healthcare professionals regarding the accuracy and sensitivity of flow cytometry is contributing to industry growth.
According to WHO 2023 statistics, chronic diseases are responsible for 41 million deaths every year at a global level. This affects people of all age groups, irrespective of their region or country. A sedentary lifestyle, unhealthy diet, and excessive tobacco and alcohol consumption are the leading risk factors for the rising prevalence of chronic diseases. Early diagnosis, accurate detection, and early intervention of the disease and its disease-causing agents are the only solutions to combat the growing prevalence of chronic diseases. This, in turn, enables healthcare professionals to use advanced technologies and highly efficient testing options, such as flow cytometry, acting as a major growth-inducing factor.
Technological Advancements
With a high prevalence of cancer, AIDS, and many other infectious diseases, there is an increasing demand to bring innovation in the flow cytometry industry that can enhance the accuracy of diagnosis and gather insights related to cell structure and functions. Key players are constantly investing in research and development to launch innovative products and instruments to facilitate flow cytometry technological advancements. In June 2023, Becton, Dickinson and Company, a global leader in medical technology, announced that it has launched an innovative automated instrument "BD FACSDuet", that can prepare samples for clinical diagnostics using flow cytometry to improve standardization and reproducibility in cellular diagnostics. The entire sample preparation process, including cocktailing, washing, and centrifuging, is automated by this product. These samples are then transferred to the physically integrated BD FACSLyric clinical flow cytometry system without any human intervention.
Government Initiatives
Government initiatives are playing a significant role in supporting the field of flow cytometry. One notable example is the establishment of the NIST Flow Cytometry Standards Consortium, which brings together industry, academia, and government to identify and address measurement and standard needs across the flow cytometry field. Additionally, government support through funds, grants, and public-private partnerships is contributing to the growth of the flow cytometry market, particularly in the context of research activities such as cancer, stem cell, and HIV studies. These initiatives are crucial in advancing the field of flow cytometry and addressing standardization issues, ultimately contributing to the development of new and innovative technologies in the market.
In August 2022, NanoCellect Biomedical Inc., a leader in developing and manufacturing microfluidic cells, announced that it received a grant of USD 1.8 million from Small Business Innovation Research (SBIR). This fund was granted to assist NanoCellect Biomedical Inc. in developing AI-based imaging flow cytometry technology. It would further help in research programs to develop novel imaging flow cytometry technology.
Growth in Demand for Cell Based Flow Cytometry
Among the technology segment, cell-based flow cytometry segment is expected to grow faster. Cell-based flow cytometry offers the advantage of high throughput and the potential to analyze millions of cells. Flow cytometry provides highly detailed information on single cells for immunotherapy clinical trials, enabling the monitoring of immune responses and the detection of abnormal cells. This technology monitors changes in immune cell phenotype, tracks therapeutic cells, and detects abnormal cells, thus offering a comprehensive view of a disease's micro-environment. In May 2023, Becton, Dickinson and Company, announced global commercial launch of an innovative cell sorting instrument, "BD FACSDiscover", a cell-based technology that will enable researchers to get more insights about cells in various areas, such as drug discovery, immuno-oncology and genomics, which is not possible in traditional flow cytometry experiments. BD FACSDiscover allows the investigation of different aspects of single-cell biology and sorts complex phenotypes for immunologic or genetic discovery.
North America Accounts for the Largest Share in Flow Cytometry Market
North America accounted for the largest share of the global flow cytometry market in 2022, with the United States being a major contributor to this dominance. The region's favorable business environment, substantial government support through funds and grants, and a robust healthcare infrastructure have driven its leadership in the flow cytometry market. Additionally, the high prevalence of HIV/AIDS and cancer has led to a growing focus on the development of treatment options for these target diseases, further propelling the demand for flow cytometry technologies.
The strong presence of key regional players, such as BD, Danaher Corporation, and Thermo Fisher Scientific, has also contributed to North America's market leadership. According to the CDC (Center for Disease Control), 6 out of 10 adults in the US are affected by a chronic disease, whereas 4 out of 10 adults in the USA have 2 or more chronic diseases. Thus, the significant prevalence of chronic and infectious diseases in this region will contribute to increased demand for rapid detection and diagnosis by flow cytometry.
Future Outlook of Global Flow Cytometry Market
Global flow cytometry market is expected to grow in the coming years, due to the growing elderly population and the increasing prevalence of infectious and chronic diseases globally. Technological advancements, research and development, government support, increasing healthcare budget, and collaborative ventures involving medical devices manufacturers, research institutions, and other healthcare providers are anticipated to drive the market growth over the forecasted period.
Key Players Landscape and Outlook
In the flow cytometry market, mergers and acquisitions, partnerships, and distribution agreements are pivotal in driving the global market. These alliances empower firms to adapt to each other's strengths, gain access to new markets and technologies, and pool resources for research and development. Distribution agreements enable companies to expand their market presence. These collaborative initiatives promote innovation, expedite product developments, and contribute to the development and growth of the global flow cytometry market. In February 2023, Luminex Corporation signed an agreement to sell all its flow cytometry & imaging (FCI) business unit assets to Cytek Biosciences. With this strategic acquisition, the company would gain insights into all facets of cellular phenotypes and morphology. There are more than 7,000 instruments, which will be under the Cytek umbrella following this acquisition that will further expand the company's global presence.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work